Danaher reported strong Q2 2026 results with net income of $870 million, or $1.23 per share, and adjusted earnings of $1.94 per share on revenue of about $6.265 billion, up 5.5% from a year earlier. The Life Sciences segment led growth, with bioprocessing orders rising and ongoing demand despite some project timing nuances. The company raised its full-year guidance, targeting adjusted core revenue growth of 3% to 4% and EPS of $8.45 to $8.60, underpinned by improving end-market conditions and ongoing growth initiatives. Management signaled the outlook could improve further as the year progresses, aiming for mid-single-digit core revenue growth by year-end. Several reports also highlight that acquisitions, such as Masimo, are contributing to the raised guidance and that the StatLab acquisition is expected to close by year-end and be accretive to EPS. Investor and insider activity data mentioned in some pieces underscores heightened interest around Danaher’s stock as it executes this growth trajectory.